Mary E. Wadlinger - Jan 1, 2025 Form 3 Insider Report for LAVA Therapeutics NV (LVTX)

Role
Director
Signature
/s/ Amy Garabedian, Attorney-in-Fact
Stock symbol
LVTX
Transactions as of
Jan 1, 2025
Transactions value $
$0
Form type
3
Date filed
1/2/2025, 09:34 AM
Previous filing
Feb 25, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LVTX Share Options (Right to Buy) Jan 1, 2025 Common Shares 20K $2.10 Direct F1
holding LVTX Share Options (Right to Buy) Jan 1, 2025 Common Shares 33.4K $1.59 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and immediately exercisable.
F2 100% of the shares underlying the option will vest on January 19, 2025, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date.